Editorial: Immune-checkpoint inhibitors in anti-cancer armamentarium: a double-edged sword in risk of developing autoimmunity and immune-related adverse effects

Aysin Tulunay Virlan; Giacomo Cafaro; Flavia Sunzini; Yannick Degboe; Maria-Ioanna Christodoulou

doi:10.3389/fonc.2024.1476475

Editorial: Immune-checkpoint inhibitors in anti-cancer armamentarium: a double-edged sword in risk of developing autoimmunity and immune-related adverse effects

Front Oncol. 2024 Aug 26:14:1476475. doi: 10.3389/fonc.2024.1476475. eCollection 2024.

Authors

Aysin Tulunay Virlan¹, Giacomo Cafaro², Flavia Sunzini¹, Yannick Degboe³, Maria-Ioanna Christodoulou^{1

4}

Affiliations

¹ School of Infection & Immunity, University of Glasgow, Glasgow, United Kingdom.
² Rheumatology Unit, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
³ Rheumatology Centre, Toulouse University Hospital and University Toulouse III, Toulouse, France.
⁴ Tumor Immunology and Biomarkers Laboratory, Basic and Translational Cancer Research Center, Department of Life Sciences, School of Sciences, European University Cyprus, Nicosia, Cyprus.

No abstract available

Keywords: anti-CTLA-4; anti-PD-1/PD-L1; autoimmunity; cancer immunotherapy; immune-checkpoint inhibitors (ICIs); immune-related adverse events (irAEs).

Publication types

Editorial